A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.

Q2 Medicine Oncotarget Pub Date : 2024-08-14 DOI:10.18632/oncotarget.28638
Zhen Li, Mohammed A Alshagawi, Rebecca A Oot, Mariam K Alamoudi, Kevin Su, Wenhui Li, Michael P Collins, Stephan Wilkens, Michael Forgac
{"title":"A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.","authors":"Zhen Li, Mohammed A Alshagawi, Rebecca A Oot, Mariam K Alamoudi, Kevin Su, Wenhui Li, Michael P Collins, Stephan Wilkens, Michael Forgac","doi":"10.18632/oncotarget.28638","DOIUrl":null,"url":null,"abstract":"<p><p>The vacuolar H<sup>+</sup>-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular compartments as well as to transport protons across the plasma membrane of various cell types, including cancer cells. We have previously shown that selective inhibition of plasma membrane V-ATPases in breast tumor cells inhibits the invasion of these cells <i>in vitro</i>. We have now developed a nanobody directed against an extracellular epitope of the mouse V-ATPase c subunit. We show that treatment of 4T1-12B mouse breast cancer cells with this nanobody inhibits V-ATPase-dependent acidification of the media and invasion of these cells <i>in vitro</i>. We further find that injection of this nanobody into mice implanted with 4T1-12B cells orthotopically in the mammary fat pad inhibits metastasis of tumor cells to lung. These results suggest that plasma membrane V-ATPases represent a novel therapeutic target to limit breast cancer metastasis.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"575-587"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325586/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.28638","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular compartments as well as to transport protons across the plasma membrane of various cell types, including cancer cells. We have previously shown that selective inhibition of plasma membrane V-ATPases in breast tumor cells inhibits the invasion of these cells in vitro. We have now developed a nanobody directed against an extracellular epitope of the mouse V-ATPase c subunit. We show that treatment of 4T1-12B mouse breast cancer cells with this nanobody inhibits V-ATPase-dependent acidification of the media and invasion of these cells in vitro. We further find that injection of this nanobody into mice implanted with 4T1-12B cells orthotopically in the mammary fat pad inhibits metastasis of tumor cells to lung. These results suggest that plasma membrane V-ATPases represent a novel therapeutic target to limit breast cancer metastasis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对 V-ATPase c 亚基的纳米抗体可抑制 4T1-12B 乳腺癌细胞向小鼠肺部转移。
液泡H+-ATP酶(V-ATP酶)是一种依赖于ATP的质子泵,其功能是控制细胞内区室的pH值,以及在包括癌细胞在内的各种细胞的质膜上运输质子。我们以前的研究表明,选择性抑制乳腺肿瘤细胞的质膜 V-ATP 酶可抑制这些细胞在体外的侵袭。我们现在开发了一种针对小鼠 V-ATPase c 亚基细胞外表位的纳米抗体。我们的研究表明,用这种纳米抗体处理 4T1-12B 小鼠乳腺癌细胞可抑制 V-ATPase 依赖性介质酸化和这些细胞在体外的侵袭。我们还发现,将这种纳米抗体注射到在乳腺脂肪垫正位植入 4T1-12B 细胞的小鼠体内可抑制肿瘤细胞向肺部转移。这些结果表明,质膜 V-ATP 酶是限制乳腺癌转移的新型治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncotarget
Oncotarget Oncogenes-CELL BIOLOGY
CiteScore
6.60
自引率
0.00%
发文量
129
审稿时长
1.5 months
期刊介绍: Information not localized
期刊最新文献
Advancements in cell-penetrating monoclonal antibody treatment. B7-H4: A potential therapeutic target in adenoid cystic carcinoma. Computed tomography-based radiomics and body composition model for predicting hepatic decompensation. Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists. Retraction: Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1